Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Serum soluble TWEAK in relapsing and progressive multiple sclerosis patients.
Multiple Sclerosis
P16 - Poster Session 16 (5:30 PM-6:30 PM)
9-002
To determine soluble TWEAK levels in a large cohort of MS and to compare TWEAK levels in i) MS patients versus controls and ii) RRMS patients vs progressive MS patients. In MS patients, to correlate soluble TWEAK levels and clinical/radiological parameters.
TWEAK (TNF weak inducer of apoptosis) is a cytokine and a member of the TNF ligand superfamily. We have been the first to show that TWEAK produced by infiltrating monocytes/macrophages contributed to neuroinflammation during multiple sclerosis (MS). Moreover, we have also recently suggested on a small cohort of patients that soluble TWEAK levels were elevated in MS and were associated with disease activity.

Serum samples from 200 patients with MS and controls were collected, and soluble TWEAK levels were evaluated by using a commercially available ELISA kit. The data of the first 103 MS patients (72 females, mean age 44 years old) and 20 controls (16 females, mean age 60 years old) are presented here.

Serum soluble TWEAK levels were significantly higher in MS patients than in controls (1031+/-388pg/ml, vs 864+/-209pg/ml, p=0.048). Although soluble TWEAK levels were higher in RRMS patients (1071+/-441pg/ml) than in progressive MS patients (972+/-267pg/ml), this did not reach statistical significance. In the RRMS patients’ group, soluble TWEAK did not correlate with EDSS (R=0.03, p=0.76)
We confirm here in an independent cohort that serum levels of TWEAK are higher in MS patients than in controls. Moreover, soluble TWEAK levels tend to be lower in progressive MS than in RRMS. Further studies examining clinical and MRI parameters (notably gadolinium enhancement) in our whole cohort are in progress
Authors/Disclosures
Xavier Ayrignac
PRESENTER 		Xavier Ayrignac has nothing to disclose.
No disclosure on file
No disclosure on file
Clarisse Carra-Dalliere No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
Pierre Labauge, MD Dr. Labauge has nothing to disclose.